Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin add-on to Glimepiride in T2DM
NCT00363519Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2006
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by Ono Pharmaceutical. Primary endpoints: Hemoglobin A1c at 12 weeks and Safety and Tolerability at 52 weeks. Started Aug 2006; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00363519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363519.